Industries > Pharma > Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018

Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018

US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India

PUBLISHED: 29 March 2018
PAGES: 333
PRODUCT CODE: PHA0297

Clear
WOOCS 2.2.1
SKU: PHA0297 Categories: , , Tags: ,

This report provides analysis and evaluation of the current and potential economic burden of Rheumatoid Arthritis (RA) in the major regions of the world comprising North America, Europe (EU5), Asia-Pacific and BRIC markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With the increased competition in the RA market resulting from the biosimilar race and new biologic entrants such as the JAK inhibitors and IL-6 inhibitors, payers now have the leverage to enact on the cost-containment of the drug category that has been experiencing high unit cost increases year after year. The blockbuster drugs of the anti-TNF category such as, Humira and Enbrel along with Remicade have been the market leaders in RA treatment since their launch however the rising biosimilars especially to Remicade and Enbrel are posing threats to their global market shares.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 333-page report you will receive 53 tables and 88 figures – all unavailable elsewhere.

The 333-page report provides clear detailed insight into the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Provides a brief history of rheumatoid arthritis, treatment options, marketed drugs and pipeline products.

• Discusses the global pricing & reimbursement for therapeutic drugs, factors affecting pricing & reimbursement, price negotiations & discounts and reimbursement policies.

• Discusses Health Economics and Outcomes Research (HEOR), Economic Value Planning, Cost-Effectiveness analysis as well as patent expiry and effects on pricing.

• Discusses Health Technology Assessment (HTA) in market access, key benefits of HTA, HTA regulatory agencies.

• Discusses the healthcare system, healthcare expenditure, key formularies, role of pharmacists, regulatory & approval process, pricing & reimbursement process, HTA, cost of rheumatoid arthritis treatment and payer insight, of these national markets:
• The US
• Canada
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• Australia
• Brazil
• Russia
• India
• China

Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018

• Discusses parallel import in the US and Europe

Visiongain’s study is intended for anyone requiring commercial analyses for the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. You find data, trends and predictions.

Buy our report today Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018


Download sample pages

Complete the form below to download your free sample pages for Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories